Thalidomide analogs regulatory update

ENMD received U.S. Patent Nos. 5,712,291 and 6,071,948 covering the use of thalidomide analogs, including EM-138 and amino-thalidomide derivatives, as antiangiogenic agents to treat cancer, blindness and chronic inflammatory diseases. ENMD's thalidomide analogs are in preclinical development. ...